
Episode 61: Personalising Anti-VEGF Treatment in Neovascular AMD: Does Phenotype Matter?
Dr. Sarah Mrejen, Associate Professor Salomon Cohen, and Associate Professor Dinah Zur explore how neovascular AMD phenotype may influence imaging choices, patient dialogue, and treatment plans. From proactive vs. conservative strategies to new anti-VEGF agents and PCV diagnosis, this expert-led discussion offers key insights into personalising care in retinal disease.